A5042022906- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Renal cell carcinoma treatment
- MRI in cancer diagnosis
- Medical Imaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Breast Cancer Treatment Studies
Mansoura University
2019
King Abdullah International Medical Research Center
2011-2015
Saitama International Medical Center
2011
The aim of our study was to evaluate whether a panel biomarkers, prospectively analysed might be able predict patients' clinical outcome more accurately than RAS status alone. K-RAS (exons 2, 3, 4) wild type colorectal cancer patients, candidates second/third-line cetuximab with chemotherapy were allocated into 2 groups on the basis their profile: favourable (BRAF and PIK3CA exon 20 type, EGFR GCN ≥ 2.6, HER-3 Rajkumar score ≤ 8, IGF-1 immunostaining < 2) or unfavourable (any previous...
To assess the role of 1H-magnetic resonance spectroscopy (1H-MRS) in confirmation pathological complete response after neoadjuvant chemotherapy breast cancer.Forty-seven cases (53.72 ± 8.53 years) were evaluated using magnetic imaging (MRI) and 1H-MRS with choline (Cho) signal-to-noise ratio (SNR) measured followed by histopathology ROC analyses.Twelve patients had response, 35 residual disease. Mean age was 53.72 years. The mean tumour size before (NAC) 4.21 0.99 cm NAC 0.9 0.44 cm.Positive...
596 Background: Many markers for a “beyond-RAS” selection of CRC patients receiving cetuximab have been suggested, but none entered clinical practice mainly because prospective validation was lacking. Aim our study to evaluate if molecular profile prospectively analysed able predict patients’ outcome more accurately than RAS status alone. Methods: K-RAS (exons 2, 3, 4) wild-type patients, candidates second/third-line with chemotherapy were allocated, after informed consent, into 2 groups on...
3591 Background: Translational research identified numerous putative markers for a “beyond-k-RAS” selection of colorectal cancer patients receiving cetuximab, but none these entered clinical practice mainly because prospective validation is lacking. The aim our study was to evaluate whether panel biomarkers, prospectively analysed may be able predict patients’ outcome more accurately than k-RAS status alone. Methods: Metastatic, K-RAS wild type patients, candidate receive second/third-line...
Objective: The aim of this work was to evaluate Multidetector Computed Tomography (MDCT) findings hepatic manifestation in common malignant hematological disorders. Materials and Methods: This retrospective study included 300 patients with different types They were 119 female 181 male (mean age, 45.4 year; range, 5-70 years). most disorder Non-Hodgkin lymphoma (NHL) detected 192/300 (64%) then Hodgkin disease (HD) 40/300 (13.3%) patients. All had ultrasonography. Clinical evaluation...